LENZ Therapeutics is betting big on a newly approved eye drop that could help people with age-related trouble reading up close, and it plans to start selling it soon. The upside hinges on whether patients and doctors switch from an existing option—and whether a one-product company can avoid surprises once the drug is widely used.Read more